Literature DB >> 16516184

Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia.

H Nandeesha1, B C Koner, L N Dorairajan, S K Sen.   

Abstract

BACKGROUND: BPH is a multifactorial disease. Several studies have elucidated the role of hormones and growth factors in its etiology. Insulin is a growth-stimulating hormone. Previous studies have reported the association between hyperinsulinemia, dyslipidemia and BPH in patients with metabolic disorders like diabetes. We evaluated insulin and lipid profile parameters in non-diabetic BPH cases and correlated it with prostate size.
METHODS: 50 symptomatic BPH cases and 38 controls were included in this study. Fasting serum insulin concentrations were measured by radioimmunoassay. Insulin resistance was assessed by HOMA. Fasting glucose, total cholesterol and triglycerides were quantified by enzymatic methods. HDL-cholesterol was quantified by phosphotungstate magnesium chloride method. LDL-cholesterol was calculated by Friedwald's formula.
RESULTS: Fasting serum insulin, HOMA, total cholesterol, and LDL-cholesterol were significantly higher and HDL-cholesterol was significantly lower in cases as compared to controls. Insulin was significantly associated with prostate size, cholesterol, triglycerides, VLDL-cholesterol and LDL-cholesterol in BPH cases. Stepwise regression analysis showed insulin as an independent risk factor in the development of BPH.
CONCLUSIONS: Hyperinsulinemia associated with insulin resistance is an independent risk factor in the development of BPH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516184     DOI: 10.1016/j.cca.2006.01.019

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  49 in total

1.  Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume.

Authors:  Jay H Fowke; Sharon Phillips; Tatsuki Koyama; Susan Byerly; Raoul Concepcion; Saundra S Motley; Peter E Clark
Journal:  BJU Int       Date:  2012-06-22       Impact factor: 5.588

2.  Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.

Authors:  Ajit Vikram; Gopabandhu Jena; Poduri Ramarao
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

3.  The comparison of GLUT-4 and nNOS expression in diabetic and non-diabetic patients with BPH/LUTS.

Authors:  Alper Otunctemur; Huseyin Besiroglu; Murat Dursun; Levent Ozcan; Emre Can Polat; Adnan Somay; Nurver Ozbay; Kutan Ozer; Emin Ozbek
Journal:  Int Urol Nephrol       Date:  2015-04-03       Impact factor: 2.370

Review 4.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

Review 5.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 6.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

Review 7.  Stimulators and activators of soluble guanylate cyclase for urogenital disorders.

Authors:  Fabiola Z Mónica; Edson Antunes
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 8.  Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity.

Authors:  Anne K Mongiu; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

Review 9.  Diabetes and benign prostatic hyperplasia: emerging clinical connections.

Authors:  Aruna V Sarma; J Kellogg Parsons
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

10.  The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: a review.

Authors:  K Stamatiou; M Lardas; E Kostakos; V Koutsonasios; E Michail
Journal:  Adv Urol       Date:  2009-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.